GO:0006491 N-glycan processing: ER Quality Control Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006491 N-glycan processing describes the sequential enzymatic remodeling of asparagine-linked glycans on newly synthesized proteins, primarily in the endoplasmic reticulum and Golgi apparatus.
• N-glycan processing is essential for glycoprotein folding, quality control, and ER-associated degradation (ERAD) decisions.
• Key enzymes include glycosidases (e.g., MAN1B1, GANAB) and glycosyltransferases (e.g., MGAT1, B4GALT1) that act in an ordered manner.
• Defects in N-glycan processing are linked to cancer progression, immune evasion, and congenital disorders of glycosylation.
• CRISPR knockout, point mutation, and knock-in models enable causal dissection of N-glycan processing genes in human cells.
• Research methods include glycomics, lectin profiling, and CRISPR library screening to identify regulators of N-glycan processing.
Description
N-glycan processing (GO:0006491) is the biological process by which asparagine-linked oligosaccharides on glycoproteins are trimmed and rebuilt by a series of glycosidases and glycosyltransferases as proteins transit the secretory pathway. This process begins in the endoplasmic reticulum (ER) with the removal of glucose residues and specific mannose residues, and continues in the Golgi apparatus with the addition of N-acetylglucosamine, galactose, fucose, and sialic acid. The resulting glycan structures influence protein folding, stability, trafficking, and interactions with lectin chaperones. For researchers, N-glycan processing is a central node in ER quality control, determining whether a glycoprotein is retained for folding, retrotranslocated for ER-associated degradation (ERAD), or selected for ER-to-lysosome-associated degradation. Dysregulated N-glycan processing is implicated in cancer, where altered glycosylation promotes invasion and immune evasion, and in macrophage biology, where it modulates antibody-dependent cellular phagocytosis. Understanding the enzymes and regulatory mechanisms of this process is therefore critical for therapeutic development and for interpreting glycoproteomic data.
N-glycan processing At A Glance
| GO ID | GO:0006491 |
|---|---|
| GO term | N-glycan processing |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Sequential trimming and extension of N-linked glycans on glycoproteins |
| Subcellular location | Endoplasmic reticulum and Golgi apparatus |
| Key enzymes | Glycosidases (e.g., MAN1B1, GANAB) and glycosyltransferases (e.g., MGAT1, B4GALT1) |
| Related processes | Protein folding, ERAD, ER-to-lysosome-associated degradation |
What Is GO:0006491?
N-glycan processing (GO:0006491) is the series of enzymatic reactions that modify N-linked glycans attached to asparagine residues on proteins, starting in the ER and continuing in the Golgi, to produce mature glycan structures.
Why Is N-glycan processing Important in Cell Biology?
N-glycan processing is essential for proteostasis and cell signaling because it determines the fate of newly synthesized glycoproteins, influencing their folding, trafficking, and degradation. It also shapes the glycan landscape of the cell surface, which controls interactions with lectins, antibodies, and immune cells. Consequently, perturbations in this process underlie diverse pathologies, including cancer and congenital disorders of glycosylation.
• Controls glycoprotein folding and quality control in the ER.
• Determines ERAD versus ER-to-lysosome-associated degradation of misfolded proteins.
• Regulates cell surface glycan structures that mediate cell-cell and cell-matrix interactions.
• Modulates immune recognition, including antibody-dependent cellular phagocytosis.
• Implicated in cancer progression through altered glycosylation.
• Provides targets for therapeutic intervention in glycosylation disorders.
• Essential for recombinant glycoprotein production in biotechnology.
• Influences viral entry and immune evasion via glycan shielding.
• Required for proper development and tissue homeostasis.
• Enables functional glycomics and biomarker discovery.
What Happens During N-glycan processing?
ER trimming and lectin chaperone cycle
In simple terms: In the ER, sugar residues are trimmed to help proteins fold correctly.
After transfer of the Glc3Man9GlcNAc2 precursor to asparagine, glucosidases I and II remove glucose residues, allowing the glycoprotein to interact with lectin chaperones calnexin and calreticulin. Further trimming by ER mannosidase I (MAN1B1) generates Man8GlcNAc2, a key signal for ERAD if folding fails.
Golgi-dependent glycan extension
In simple terms: In the Golgi, sugars are added to build complex N-glycans.
Proteins that pass ER quality control transit to the Golgi, where mannosidases (e.g., MAN2A1) trim mannose residues and glycosyltransferases (e.g., MGAT1, MGAT2, B4GALT1) add N-acetylglucosamine, galactose, fucose, and sialic acid. This sequential processing generates hybrid and complex N-glycans that determine glycoprotein function.
ER-to-lysosome-associated degradation (ERLAD)
In simple terms: Some misfolded proteins are sent to lysosomes instead of being degraded in the cytosol.
N-glycan processing can select ERAD-resistant misfolded proteins for ER-to-lysosome-associated degradation, a pathway that bypasses the proteasome and delivers cargo to lysosomes. This decision depends on specific glycan structures generated during processing.
Regulation by glycosidase and glycosyltransferase expression
In simple terms: The levels of processing enzymes control the final glycan structure.
The expression and localization of Golgi-resident N-glycan processing enzymes are tightly regulated to ensure ordered processing. In plants, trafficking and localization of these enzymes are critical for proper glycan maturation. In mammalian cells, enzyme competition and substrate availability influence glycan heterogeneity.
Key Genes Involved in GO:0006491 N-glycan processing
The following genes encode key enzymes and lectins that mediate N-glycan processing and its quality control functions.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MAN1B1 | ER mannosidase I; generates Man8GlcNAc2 for ERAD | Target for studying ERAD and congenital disorders |
| GANAB | Golgi alpha-mannosidase II; trims mannose in Golgi | Model for Golgi processing and cancer glycosylation |
| MGAT1 | N-acetylglucosaminyltransferase I; initiates hybrid/complex N-glycans | Knockout alters glycan profile and cell signaling |
| MGAT2 | N-acetylglucosaminyltransferase II; extends complex N-glycans | Target for glycoengineering |
| B4GALT1 | Beta-1,4-galactosyltransferase; adds galactose | Model for galactosylation and immune recognition |
| FUT8 | Alpha-1,6-fucosyltransferase; adds core fucose | Knockout affects antibody function and ADCC |
| ST6GAL1 | Alpha-2,6-sialyltransferase; adds sialic acid | Linked to cancer metastasis and immune evasion |
| CALR | Calreticulin; lectin chaperone in ER | Studied for glycoprotein folding and ER quality control |
| CANX | Calnexin; lectin chaperone in ER | Model for chaperone cycle and ERAD |
| UGGT1 | UDP-glucose:glycoprotein glucosyltransferase; reglucosylates misfolded proteins | Key for ER quality control |
| EDEM1 | ER degradation-enhancing alpha-mannosidase-like protein | Target for ERAD studies |
| OS9 | Lectin that recognizes trimmed glycans for ERAD | Model for ERAD substrate recognition |
| DERL1 | Derlin-1; retrotranslocation channel | Studied in ERAD of glycoproteins |
| SEL1L | HRD1 complex component; ERAD lectin | Target for ERAD pathway analysis |
| MAN2A1 | Golgi alpha-mannosidase II; mannose trimming | Knockout alters complex N-glycan formation |
| B3GNT2 | Beta-1,3-N-acetylglucosaminyltransferase; poly-N-acetyllactosamine synthesis | Model for glycan extension |
| NGLY1 | Peptide:N-glycanase; deglycosylates ERAD substrates | Linked to NGLY1 deficiency |
How Is N-glycan processing Regulated?
N-glycan processing is regulated at multiple levels, including enzyme expression, localization, and substrate availability. In the ER, the lectin chaperone cycle and redox conditions influence trimming and folding decisions. Golgi-resident enzymes are organized in a sequential manner, and their trafficking and retention are critical for ordered processing. Additionally, ER stress and the unfolded protein response can modulate the expression of glycosidases and glycosyltransferases to adapt processing capacity.
N-glycan processing and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MAN1B1 | Congenital disorder of glycosylation | Knockout HEK293 cells; point mutation knock-in |
| FUT8 | Altered antibody effector function | Knockout CHO cells; glycoengineered antibodies |
| ST6GAL1 | Cancer metastasis and immune evasion | Overexpression in cancer cell lines; knockout |
| NGLY1 | NGLY1 deficiency (neurodevelopmental) | Knockout iPSCs; patient-derived fibroblasts |
| MGAT1 | Cancer glycosylation and signaling | Knockout in cancer cell lines; lectin profiling |
Cancer
Altered N-glycan processing is a hallmark of cancer, contributing to invasion, metastasis, and immune evasion. For example, increased sialylation and fucosylation can promote tumor progression and modulate interactions with immune cells.
Immune modulation
N-glycan processing in macrophages inhibits antibody-dependent cellular phagocytosis, highlighting its role in immune regulation. Glycan structures on therapeutic antibodies, such as core fucose, determine Fc receptor binding and effector function.
Congenital disorders of glycosylation
Mutations in genes encoding N-glycan processing enzymes, such as MAN1B1, cause congenital disorders of glycosylation with multisystem phenotypes. These disorders underscore the importance of proper glycan processing for development and homeostasis.
Neurodegeneration
Defects in ER quality control and N-glycan processing can lead to accumulation of misfolded proteins, contributing to neurodegenerative diseases. The ER-to-lysosome-associated degradation pathway is particularly relevant for clearing aggregation-prone proteins.
From N-glycan processing-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of MAN1B1 impair ERAD? | CRISPR knockout of MAN1B1 in HEK293 cells |
| How does core fucosylation affect ADCC? | FUT8 knockout in antibody-producing cells |
| What is the role of ST6GAL1 in metastasis? | Overexpression and knockout in cancer cell lines |
| Can a point mutation in MGAT1 alter glycan branching? | CRISPR point mutation knock-in in CHO cells |
| How does NGLY1 deficiency affect glycoprotein degradation? | Knockout iPSCs differentiated into neurons |
| Does tagged GANAB localize correctly in Golgi? | Knock-in of fluorescent tag in HeLa cells |
How to Study the N-glycan processing Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lectin microarray | Relative abundance of glycan epitopes | Profiling N-glycan changes in knockout cells |
| Mass spectrometry glycomics | Detailed glycan structures | Characterizing processing intermediates |
| Glycoproteomics | Site-specific glycan occupancy | Mapping N-glycosylation sites on glycoproteins |
| CRISPR knockout screen | Genes required for glycan processing | Identifying novel regulators |
| Fluorescence microscopy | Subcellular localization of enzymes | Studying Golgi trafficking |
| Flow cytometry with lectins | Cell surface glycan levels | Assessing sialylation and fucosylation |
| Western blot | Protein expression and ERAD | Monitoring degradation of misfolded glycoproteins |
| qRT-PCR | mRNA levels of processing enzymes | Validating transcriptional regulation |
Glycomics and lectin profiling
Mass spectrometry-based glycomics and lectin microarrays are used to profile N-glycan structures and detect changes upon genetic perturbation. These methods provide a global view of processing intermediates and end products.
CRISPR screening
Genome-wide CRISPR knockout screens coupled with lectin staining or glycan-sensitive reporters can identify genes required for specific N-glycan processing steps. Such screens have revealed regulators of glycosylation and immune recognition.
Proteomics and glycoproteomics
Site-specific glycoproteomics using mass spectrometry identifies occupied N-glycosylation sites and their glycan compositions, enabling functional studies of processing enzymes. This approach is valuable for assessing ERAD substrates and secreted glycoproteins.
Imaging and subcellular localization
Fluorescence microscopy of tagged processing enzymes (e.g., GANAB, MAN2A1) reveals their Golgi localization and trafficking dynamics. Live-cell imaging can track glycoprotein transport from ER to Golgi.
How CRISPR Can Be Used to Study GO:0006491 N-glycan processing
Knockout
CRISPR knockout of N-glycan processing genes (e.g., MAN1B1, FUT8, MGAT1) in human cell lines enables loss-of-function studies to assess glycan remodeling, ERAD efficiency, and cell surface glycan presentation. Knockout models are essential for validating enzyme specificity and pathway redundancy.
Point Mutation
CRISPR point mutation knock-in can introduce disease-associated missense mutations in processing enzymes to model congenital disorders of glycosylation and dissect catalytic residues. Such models help distinguish loss-of-function from dominant-negative effects.
Knock-in
Knock-in of epitope tags or fluorescent proteins into endogenous loci (e.g., GANAB, MAN2A1) allows real-time tracking of enzyme localization and trafficking in the secretory pathway. This approach preserves endogenous regulatory elements and expression levels.
Overexpression
CRISPR activation or cDNA overexpression of processing enzymes (e.g., ST6GAL1, B4GALT1) can drive specific glycan modifications and test their impact on cell behavior, such as invasion or immune recognition. Overexpression models are useful for gain-of-function studies and bioproduction.
How EDITGENE Supports N-glycan processing Research
Researchers studying N-glycan processing-related genes often need to determine whether a candidate gene is causally involved in glycan remodeling, ER quality control, or disease-associated glycosylation changes. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for N-glycan processing research.
Frequently Asked Questions About N-glycan processing
What is N-glycan processing?
N-glycan processing (GO:0006491) is the enzymatic trimming and extension of N-linked glycans on proteins, primarily in the ER and Golgi, to control protein folding and function.
What genes are involved in N-glycan processing?
Key genes include MAN1B1, GANAB, MGAT1, MGAT2, B4GALT1, FUT8, ST6GAL1, and lectin chaperones like CALR and CANX.
Where does N-glycan processing occur?
It begins in the endoplasmic reticulum and continues in the Golgi apparatus.
Why is N-glycan processing important for protein folding?
It generates glycan signals that recruit lectin chaperones and determine ERAD versus folding outcomes.
How is N-glycan processing linked to cancer?
Altered processing leads to tumor-associated glycan structures that promote invasion and immune evasion.
What diseases are associated with defects in N-glycan processing?
Congenital disorders of glycosylation, cancer, and neurodegenerative conditions.
How can I study N-glycan processing using CRISPR?
Use knockout, point mutation, knock-in, or overexpression models to perturb specific enzymes and analyze glycan changes.
What methods are used to analyze N-glycan processing?
Lectin microarrays, mass spectrometry glycomics, glycoproteomics, and flow cytometry.
What is the role of MAN1B1 in N-glycan processing?
MAN1B1 is an ER mannosidase that generates Man8GlcNAc2, a signal for ERAD.
How does fucosylation affect antibody function?
Core fucosylation by FUT8 modulates antibody-dependent cellular phagocytosis and Fc receptor binding.
Conclusion
N-glycan processing (GO:0006491) is a fundamental biological process that governs glycoprotein folding, quality control, and cell surface recognition. Its dysregulation contributes to cancer, immune disorders, and congenital diseases, making it a rich area for therapeutic targeting. CRISPR-based models and advanced glycomics are accelerating the discovery of new regulators and disease mechanisms.
References
- 1. Ruddock LW et al.. 2006. N-glycan processing in ER quality control.. J Cell Sci 119(Pt 21):4373-80 PMID: 17074831
- 2. Dünser K et al.. 2025. Trafficking and localization of Golgi-resident N-glycan processing enzymes in plants.. Front Plant Sci 16:1624949 PMID: 40786940
- 3. Lin Y et al.. 2024. The role of N-glycosylation in cancer.. Acta Pharm Sin B 14(3):1098-1110 PMID: 38486989
- 4. Díaz de León JSA et al.. 2023. Macrophage N-glycan processing inhibits antibody-dependent cellular phagocytosis.. Glycobiology 33(12):1182-1192 PMID: 37792857
- 5. Fregno I et al.. 2021. N-glycan processing selects ERAD-resistant misfolded proteins for ER-to-lysosome-associated degradation.. EMBO J 40(15):e107240 PMID: 34152647
- 6. Aebi M et al.. 2010. N-glycan structures: recognition and processing in the ER.. Trends Biochem Sci 35(2):74-82 PMID: 19853458
- 7. Tomiya N et al.. 2004. Comparing N-glycan processing in mammalian cell lines to native and engineered lepidopteran insect cell lines.. Glycoconj J 21(6):343-60 PMID: 15514482
- 8. Trombetta ES et al.. 2001. N-glycan processing and glycoprotein folding.. Adv Protein Chem 59:303-44 PMID: 11868276
